Discover new efficacy data from MAIA’s Phase 2 THIO-101 #clinicaltrial evaluating THIO sequenced with the immune CPI cemiplimab (Libtayo®) in patients with advanced #NSCLC: https://bit.ly/4aMMFlZ
MAIA Biotechnology, Inc.
Biotechnology
Chicago, Illinois 5,653 followers
MAIA Biotechnology is a targeted therapy, immuno-oncology company focused on development of first-in-class drugs
About us
MAIA Biotechnology is a targeted therapy, immune-oncology company, focused on development and commercialization of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. A publicly traded company based in Chicago, MAIA (NYSE American: MAIA) is led by a passionate, principled and highly experienced Management Team with significant drug development experience, committed to advancing promising agents into human clinical trials. MAIA’s business strategy is designed to advance a strong value proposition for its portfolio of potentially novel compounds. MAIA controls risk and enhances its opportunity for success by diversifying and generating this portfolio of assets with a variety of compounds with novel mechanisms of action which have potential activity in multiple tumor types. MAIA’s business model involves placing drug candidates in their own dedicated, R&D focused subsidiary company, which is supported by the common infrastructure, management team, and resources of the MAIA enterprise. This model allows MAIA to provide more focused R&D support to each drug candidate, while also distributing shared central resources among subsidiary companies to maintain a lean, capital-efficient operating structure.
- Website
-
http://www.maiabiotech.com
External link for MAIA Biotechnology, Inc.
- Industry
- Biotechnology
- Company size
- 2-10 employees
- Headquarters
- Chicago, Illinois
- Type
- Privately Held
- Founded
- 2018
- Specialties
- Drug development, Oncology, Research, Targeted Therapy, Immmuno-Oncology, Telomere Targeting, Biotechnology, Small Molecule, Pharmaceutical, and Immunotherapy
Locations
-
Primary
Get directions
444 West Lake Street
Suite 1700
Chicago, Illinois 60606, US
Employees at MAIA Biotechnology, Inc.
-
Sergei Gryaznov
-
Jean-Manassé Théagène
Executive | Board Member I EntrepreneurI Advisor I Disruptive Thinker I Technology & Health Enthusiast I Connector I Mentor I Passionate about…
-
K. Robinson Lewis
Vice President, Head of Regulatory and Quality at MAIA Biotechnology, Inc.
-
Stan V. Smith, Ph.D.
President and CEO - Smith Economics Group, Ltd.
Updates
-
We're happy to share that Tomasz Jankowski, MD, PhD, the presenting author of MAIA’s poster at #ASCO24 and the key investigator in MAIA's Phase 2 #clinicaltrial, was selected as one of the very few authors to provide a video update. Watch Dr. Jankowski’s discussion about the progress of THIO-101 here: https://bit.ly/3RExJja #ClinicalResearch #Oncology #NSCLC
-
Thank you Cromos Pharma for partnering in this collaboration to make significant strides in cancer treatment research!
MAIA Biotechnology, Inc. and Cromos Pharma have partnered up in an innovative collaboration to advance cancer treatment. Mutual collaborative efforts are focused on THIO, a groundbreaking telomere-targeting agent for non-small cell lung cancer (NSCLC). In a trial presented at ASCO 2024, THIO demonstrated an impressive 85% disease control rate. Read more in the press release: https://lnkd.in/dsiSDg8V #cro #partnership #maiabiotechnology #clinicaltrials #cancertreatment
-
-
MAIA is developing telomere-targeting #immunotherapies for cancer treatment. Recent promising new clinical data has unveiled efficacy of our lead product candidate, THIO, in treating #NSCLC. Read more about our key findings here: https://bit.ly/3XbgXfe #Oncology
New Clinical Data Reveals MAIA Biotechnology's THIO Achieves High Efficacy In Advanced Non-Small Cell Lung Cancer Treatment - MAIA Biotechnology (AMEX:MAIA)
benzinga.com
-
Our most recent #clinical data points to THIO’s unprecedented DCR of 85%, ORR of 38%, and post-therapy patient benefits. Third-line treatment with THIO has far outperformed reported standard-of-care data in #NSCLC. Read our latest news: https://bit.ly/4bNqiy7 #Oncology
-
-
MAIA Biotechnology’s (NYSE: MAIA) Telomere Targeting Functionality Is Shown Viable By Fda’s Approval Of A Telomerase Inhibitor Agent Therapy. Read the press release here: https://lnkd.in/gFaa54wK #Biopharma #ClinicalResearch
MAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDA's Approval of a Telomerase Inhibitor Agent Therapy
ir.maiabiotech.com
-
MAIA’s newest data shows THIO’s strong outperformance against standard-of-care treatments in #NSCLC. THIO-101 clinical data showed: ORR of 38% DCR of 85% Dive into the press release: https://bit.ly/4bNqiy7 #ClinicalResearch #CancerResearch
-
-
New clinical data shows THIO’s strong efficacy in #NSCLC patients with ORR of 38% and DCR of 85% in third-line treatment surpassing the current standard-of-care. Read MAIA’s press release for highlights on the results here: https://bit.ly/4aMMFlZ #ClinicalResearch #Oncology
-
-
New efficacy data from MAIA’s Phase 2 THIO-101 clinical trial in patients with advanced #NSCLC shows an ORR of 38% and a DCR of 85% exceeding the current standard-of-care in third-line treatment. Read the press release here: https://bit.ly/4aMMFlZ #Oncology #ASCO24
-